Cocrystal Pharma, Inc. (COCP)
1.15
-0.04
(-3.36%)
USD |
NASDAQ |
Sep 24, 16:00
Cocrystal Pharma Research and Development Expense (Quarterly) : 2.142M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.142M |
| March 31, 2026 | 1.371M |
| December 31, 2025 | 1.619M |
| September 30, 2025 | 0.954M |
| June 30, 2025 | 1.122M |
| March 31, 2025 | 1.36M |
| December 31, 2024 | 2.037M |
| September 30, 2024 | 3.242M |
| June 30, 2024 | 4.308M |
| March 31, 2024 | 2.95M |
| December 31, 2023 | 4.267M |
| September 30, 2023 | 4.194M |
| June 30, 2023 | 2.801M |
| March 31, 2023 | 3.907M |
| December 31, 2022 | 3.287M |
| September 30, 2022 | 3.872M |
| June 30, 2022 | 2.361M |
| March 31, 2022 | 2.777M |
| December 31, 2021 | 2.208M |
| September 30, 2021 | 2.067M |
| June 30, 2021 | 2.652M |
| March 31, 2021 | 1.485M |
| December 31, 2020 | 0.88M |
| September 30, 2020 | 1.988M |
| June 30, 2020 | 1.896M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.209M |
| December 31, 2019 | 0.887M |
| September 30, 2019 | 1.011M |
| June 30, 2019 | 1.069M |
| March 31, 2019 | 0.855M |
| December 31, 2018 | 1.193M |
| September 30, 2018 | 1.456M |
| June 30, 2018 | 1.105M |
| March 31, 2018 | 0.862M |
| December 31, 2017 | 1.079M |
| September 30, 2017 | 1.368M |
| June 30, 2017 | 1.229M |
| March 31, 2017 | 2.045M |
| December 31, 2016 | 93.83M |
| September 30, 2016 | 2.043M |
| June 30, 2016 | 2.315M |
| March 31, 2016 | 3.286M |
| December 31, 2015 | 41.51M |
| September 30, 2015 | 2.177M |
| June 30, 2015 | 1.946M |
| March 31, 2015 | 1.56M |
| December 31, 2014 | 1.349M |
| September 30, 2014 | 0.866M |
| June 30, 2014 | 0.888M |
| March 31, 2014 | 0.967M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| CNBX Pharmaceuticals, Inc. | -- |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 52.30M |
| Fulcrum Therapeutics, Inc. | 12.23M |
| Definium Therapeutics, Inc. | 48.66M |